GURU.Markets stock price, segment price, and overall market index valuation
The company's share price XOMA Royalty
XOMA Royalty doesn't develop drugs itself, but rather holds a portfolio of royalties from drugs developed by other companies. Its share price reflects diversified and passive income from successes in the pharmaceutical industry, mitigating risk.
Share prices of companies in the market segment - Invest resource
XOMA Royalty generates revenue from royalties and license fees for the use of patented technologies and drugs developed by its partners in the pharmaceutical industry. We classify it as a "Resource Investment." The chart below illustrates how this specific biotech sector is faring.
Broad Market Index - GURU.Markets
XOMA is a biotech royalty company that holds a portfolio of licensed drug candidates and receives payments as they are developed. As a unique player, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with XOMA's performance to assess the state of this sector.
Change in the price of a company, segment, and market as a whole per day
XOMA - Daily change in the company's share price XOMA Royalty
Daily fluctuations in XOMA, a pharmaceutical royalty holder, reflect the performance of its partners. Change_co measures sensitivity to news about clinical trials of third-party drugs. This metric forms the basis for analyzing the unique business model of pharmaceutical royalties on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Invest resource
XOMA Corporation is a royalty-holding company on a portfolio of biotech assets. This chart highlights the sector's high volatility. Comparing it to XOMA's performance helps us evaluate it as a diversified and less risky bet on the industry.
Daily change in the price of a broad market stock, index - GURU.Markets
XOMA is a unique biotech company that doesn't develop its own drugs, but rather holds a portfolio of royalties from sales of other companies' drugs. The chart below shows the volatility of the biotech sector, which is interesting to compare with XOMA's approach.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization XOMA Royalty
XOMA Royalty's year-over-year performance reflects the success of its unique business model: acquiring rights to future royalties from biotech drugs. The 12-month market capitalization growth is driven by successful clinical trials of partner drugs, which brings the company closer to cash flow generation and validates the investment.
Annual dynamics of market capitalization of the market segment - Invest resource
XOMA Royalty is a unique company that owns a portfolio of royalties and potential payouts from numerous pharmaceuticals developed by other companies. This chart illustrates how its diversified yet unpredictable model, dependent on R&D success, plays out in the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
XOMA, with its biotech royalty model, offers investors a diversified exposure to the sector. Its revenue isn't dependent on the success of a single company. XOMA's stock performance is a story about how to participate in biotech growth while mitigating the risks associated with the failure of individual clinical trials.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization XOMA Royalty
XOMA, a unique royalty company, depends on the success of its partners for its market capitalization. Monthly fluctuations on the chart reflect news about clinical trials and drug approvals from which it receives or will receive royalties, making it a diversified bet on the success of the biotech industry.
Monthly dynamics of market capitalization of the market segment - Invest resource
XOMA holds a portfolio of royalties and potential future payments from numerous pharmaceuticals developed by its partners. This provides a diversified way to invest in the success of the biotech industry. The chart below illustrates the dynamics of the biotech sector, but XOMA's business model offers a different risk profile.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
XOMA Royalty owns a portfolio of pharmaceutical royalties. Its revenue comes from royalties on sales of drugs developed by other companies. This business model ensures stable cash flow and makes the stock less susceptible to general market fluctuations. The chart will reveal whether XOMA is a safe haven in the volatile world of biotech.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization XOMA Royalty
XOMA Royalty owns a portfolio of royalties from potential pharmaceuticals. Its weekly stock performance reflects a diversified bet on the success of the biotech industry. News of clinical trials from its partners is sparking investor reactions.
Weekly dynamics of market capitalization of the market segment - Invest resource
XOMA Royalty, like the entire biotech royalty sector, reacts weekly to the overall sentiment in the pharmaceutical industry. News of major M&A deals or regulatory changes impact all players. The chart shows how XOMA moves with this general trend.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
XOMA Royalty receives royalties from pharmaceuticals developed by other companies. This should ensure stable cash flow. The chart will show whether the company's shares are a defensive asset, less susceptible to market fluctuations, or whether news about specific drugs creates their own volatility.
Market capitalization of the company, segment and market as a whole
XOMA - Market capitalization of the company XOMA Royalty
XOMA Corporation's market capitalization is a diversified bet on the success of the biotech industry. The chart of this company, which holds a portfolio of royalties from multiple drugs, shows how investors view a model that allows them to profit from the success of others without spending money on R&D.
XOMA - Share of the company's market capitalization XOMA Royalty within the market segment - Invest resource
XOMA Royalty operates under a unique model, acquiring royalties and rights to future payments from pharmaceutical companies. Its market share and capitalization reflect the value of its diversified portfolio of potential revenues from dozens of drugs in development.
Market capitalization of the market segment - Invest resource
XOMA Royalty invests in future drug revenues. How big is this "pharmacy of the future"? The chart below shows the overall market capitalization of the sector. Its dynamics are a barometer of biotech innovation, reflecting how investors assess the success rate of new drugs in development.
Market capitalization of all companies included in a broad market index - GURU.Markets
XOMA's chart reveals a unique business model in biotech. The company doesn't develop drugs itself, but rather owns a portfolio of royalties from drugs developed by its partners. Its market capitalization is an estimate of the future cash flows from these royalties, making it a less risky bet on the success of the entire pharmaceutical industry.
Book value capitalization of the company, segment and market as a whole
XOMA - Book value capitalization of the company XOMA Royalty
XOMA Royalty's book value is its unique portfolio of licensing agreements and royalty rights from sales of dozens of pharmaceuticals. This metric reflects the valuation of its rights to future cash flows from biotech innovations. The chart below shows how the value of this portfolio has grown.
XOMA - Share of the company's book capitalization XOMA Royalty within the market segment - Invest resource
XOMA Royalty doesn't own any laboratories, but its balance sheet reflects a stake in the future success of dozens of biopharmaceutical companies. Its assets are royalty rights indirectly tied to its partners' actual R&D centers and factories. The chart shows how its unique business model allows it to control a stake in the industry's tangible assets.
Market segment balance sheet capitalization - Invest resource
XOMA Royalty is a unique "asset-light" model. Pharmaceuticals, as the chart shows, are capital-intensive. XOMA, however, doesn't develop drugs. It owns a portfolio of royalties from sales of drugs developed by other companies, generating income without the risk of R&D.
Book value of all companies included in the broad market index - GURU.Markets
XOMA Royalty doesn't have its own laboratories, but its balance sheet reflects the value of a portfolio of royalties from dozens of real pharmaceutical products. The chart below indirectly shows how this portfolio, linked to the physical production and sale of drugs, has grown.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - XOMA Royalty
XOMA doesn't have its own laboratories. Its high valuation is a premium for its diversified portfolio of royalties from multiple drugs. The chart below shows how the market valued this smart and less risky biotech business model.
Market to book capitalization ratio in a market segment - Invest resource
XOMA Royalty owns a portfolio of royalties from potential pharmaceutical companies. Its value lies in the likelihood of success of these drugs. The chart shows how the market values this diversified but risky portfolio of intangible assets.
Market to book capitalization ratio for the market as a whole
XOMA Royalty owns a portfolio of rights to receive royalties from the sales of various pharmaceuticals. Its business model is to collect these payments. Unlike the average valuation on this chart, its value is directly linked to the discounted value of future cash flows from its portfolio. This is a financial, rather than scientific, approach to investing in biotech.
Debts of the company, segment and market as a whole
XOMA - Company debts XOMA Royalty
XOMA Royalty has a unique business model: it owns a portfolio of royalties and license fees from various pharmaceuticals. This chart shows its financial structure. The company uses capital to purchase these future cash flows from biotech companies, creating a diversified and predictable source of income.
Market segment debts - Invest resource
XOMA Royalty is a unique biotech company that doesn't develop drugs but instead holds a portfolio of royalties and potential payments from more than 70 drugs being developed by its partners. Its debt policy is generally conservative. This chart shows how the company manages its capital while anticipating revenue from its diversified asset portfolio.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio XOMA Royalty
XOMA Royalty generates revenue from licensing fees for the use of biotech patents. Unlike drug developers, its business is less capital-intensive. This chart shows how the company uses debt, likely to acquire new royalties. It helps evaluate its portfolio expansion strategy and financial discipline.
Market segment debt to market segment book capitalization - Invest resource
XOMA Royalty is a company that holds a portfolio of royalties on potential future drugs. This chart shows the leverage in the biotech investment sector. It helps understand how companies with this model use capital to acquire new assets, diversifying the risks associated with the success of clinical trials.
Debt to book value of all companies in the market
XOMA Royalty generates revenue from licensing biotech assets, making it less capital-intensive than R&D companies. Debt can be used to purchase new royalties. This chart of overall market leverage provides a basis for comparison. How aggressively does XOMA use debt to expand its portfolio compared to the overall investment climate?
P/E of the company, segment and market as a whole
P/E - XOMA Royalty
XOMA Royalty holds a portfolio of royalties and potential payouts from numerous pharmaceutical and biotech companies. This chart shows how investors evaluate a diversified bet on the success of the biotech industry. The company receives revenue when its partner drugs reach certain milestones, without incurring R&D risks.
P/E of the market segment - Invest resource
XOMA Royalty holds a portfolio of royalties and potential payments from over 70 pharmaceuticals developed by its partners. The company monetizes its extensive expertise in antibody discovery. This chart shows the average valuation for the resource investment sector, reflecting how investors value the unique royalty model in biotech.
P/E of the market as a whole
XOMA Royalty is a company that doesn't develop drugs, but rather holds a portfolio of rights to receive royalties from sales of drugs developed by other companies. Its business model is to generate stable cash flows from successful drugs. This general sentiment curve has little impact on the company, as its revenue is determined by patents and sales volumes of specific drugs.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company XOMA Royalty
XOMA Royalty is a company that holds a portfolio of royalties and license fees from various pharmaceutical and biotech drugs. This graph reflects the combined market expectations for these drugs. The company's valuation represents a diversified bet on the biotech industry without the risks associated with the failure of its own clinical trials.
%20P%2FE%20XOMA%20Royalty&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-XOMA-Royalty&v=1772499962300 "Chart of the company's future (projected) P/E XOMA Royalty")
Future (projected) P/E of the market segment - Invest resource
XOMA Royalty owns a portfolio of royalties and potential payouts from pharmaceutical companies. It doesn't develop drugs itself, but rather relies on the success of others. This chart shows how the market values its diversified portfolio of biotech bets. Comparing its profit projections to the sector reflects the premium it places on its less-risky business model.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Invest%20resource&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Invest-resource&v=1772499962301 "Future (projected) P/E graph of the market segment - Invest resource")
Future (projected) P/E of the market as a whole
XOMA Royalty holds a portfolio of royalties on potential payouts from pharmaceuticals developed by its partners. This unique business model is based on betting on the success of others' R&D. This overall risk appetite profile influences the valuation of the biotech sector as a whole, which determines the value of XOMA's assets and future transactions.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772499962306 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit XOMA Royalty
XOMA Royalty is a unique biotech company that doesn't develop drugs, but rather holds a portfolio of royalties and potential payments from over 70 drugs developed by other companies. Its profits are passive income from the successes of its partners. This chart shows how diversified bets on other companies' innovations generate cash flow.
Profit of companies in the market segment - Invest resource
XOMA Royalty is a unique company that holds a portfolio of royalties and milestone payments from over 70 pharmaceutical programs. It doesn't conduct its own developments, but rather invests in others'. Its sector's overall profitability chart reflects the state of the entire biopharmaceutical industry: the more successful drugs enter the market, the higher XOMA's revenue from its diversified assets.
Overall market profit
XOMA Royalty holds a portfolio of royalties and potential payments from pharmaceutical companies that have developed drugs based on its technologies. The company's business model allows it to profit from the successes of other players in the biotech industry. This makes XOMA a diversified fund whose revenue reflects the overall progress and profitability of drug development.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company XOMA Royalty
XOMA Royalty holds a portfolio of royalties and license fees from various pharmaceuticals. This chart shows expected sales for drugs developed by its partners. The company's business model allows it to profit from advances in biotech without bearing the direct risks of clinical development.
%20profit%20of%20the%20company%20XOMA%20Royalty&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-XOMA-Royalty&v=1772499962318 "Graph of future (projected) profit of the company XOMA Royalty")
Future (predicted) profit of companies in the market segment - Invest resource
XOMA Royalty holds a portfolio of royalties and license fees from various pharmaceutical and biotech companies. This chart shows projected revenue trends for the entire biotech sector. It allows one to assess how a diversified royalty portfolio provides the company with stable income, regardless of the success of a single drug.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Invest%20resource&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Invest-resource&v=1772499962320 "Graph of future (predicted) profits of companies in a market segment - Invest resource")
Future (predicted) profit of the market as a whole
XOMA Royalty's profit forecast depends on the success of the drugs for which it receives royalties. This chart reflects expected sales of drugs developed by its partners. The company's business model is focused on generating passive income from pharmaceutical intellectual property, making it less risky than traditional biotech companies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772499962323 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - XOMA Royalty
XOMA Royalty doesn't develop drugs, but rather holds royalties from sales of its partners' drugs. This chart shows how investors value this diversified stream of future revenue. The multiple reflects the attractiveness of a business model that allows for revenue from biotech successes without R&D expenditures.
P/S market segment - Invest resource
XOMA Royalty generates revenue from royalties and licensing fees for the use of partner antibodies in pharmaceuticals. The company's business model is focused on generating passive income from other companies' developments. This chart shows the average valuation for biotech investing companies, allowing one to assess the attractiveness of XOMA's royalty portfolio for revenue generation.
P/S of the market as a whole
XOMA Royalty is a company that holds a portfolio of royalties and potential payouts from over 70 pharmaceuticals developed by other companies. Its revenue comes from passive income generated by the success of these other companies' drugs. This chart, showing the average revenue estimate for XOMA, illustrates how the market values this diversified and less risky biotech investment model.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company XOMA Royalty
XOMA Royalty is a company that holds a portfolio of royalties and potential payments from pharmaceutical companies. It doesn't develop drugs itself, but rather receives revenue when its partners' drugs are successful. This chart shows how investors estimate the total future returns of this diversified portfolio of biotech assets.
%20P%2FS%20XOMA%20Royalty&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-XOMA-Royalty&v=1772499962334 "The graph of the company's future (projected) P/S XOMA Royalty")
Future (projected) P/S of the market segment - Invest resource
XOMA Royalty holds a portfolio of royalties and potential payouts from pharmaceutical companies. This chart compares the company's estimated future earnings with those of other resource investors. It shows how investors evaluate its diversified asset mix and the likelihood of receiving royalties based on the market success of its partner drugs.
%20P%2FS%20market%20segment%20graph%20-%20Invest%20resource&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Invest-resource&v=1772499962335 "Future (projected) P/S market segment graph - Invest resource")
Future (projected) P/S of the market as a whole
XOMA Royalty holds a portfolio of potential royalties from pharmaceuticals at various stages of development. Its business model is a diversified bet on the success of biotech innovations. The growth in XOMA's portfolio value reflects the overall optimism about the future of the pharmaceutical industry, which is reflected in this chart.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772499962337 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales XOMA Royalty
XOMA Royalty is a biotech company whose business model is to acquire royalties from potential future sales of drugs developed by other companies. This chart shows the revenue XOMA receives from its partners once their drugs hit the market and begin generating sales.
Sales of companies in the market segment - Invest resource
XOMA Royalty holds a portfolio of royalties and license fees from various pharmaceutical and biotech companies. Instead of developing drugs, the company invests in others' successes, receiving a percentage of sales. This chart shows overall pharmaceutical sales, the growth of which directly increases XOMA's revenue from its diversified asset portfolio.
Overall market sales
XOMA Royalty is a company with a unique business model: it receives royalties from dozens of pharmaceutical and biotech drugs developed by other companies. This overall economic activity affects XOMA through overall healthcare costs. The more drugs its partners sell, the higher its passive income.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company XOMA Royalty
XOMA Royalty holds a portfolio of royalties and potential payments from pharmaceutical companies. The company does not develop drugs itself, but instead earns revenue when its partners' drugs achieve commercial success. This chart shows aggregate analyst expectations for approval probabilities and sales volumes for a range of drugs developed by other companies.
%20sales%20of%20the%20company%20XOMA%20Royalty&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-XOMA-Royalty&v=1772499962352 "Schedule of future (projected) sales of the company XOMA Royalty")
Future (projected) sales of companies in the market segment - Invest resource
XOMA Royalty holds a portfolio of royalties from potential future sales of pharmaceuticals developed by its partners. This chart shows projected revenues for the entire pharmaceutical sector. While it provides a general overview, XOMA's success depends on the successful clinical trials and commercialization of the specific drugs for which it receives royalties.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Invest%20resource&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Invest-resource&v=1772499962355 "Schedule of future (projected) sales of companies in the market segment - Invest resource")
Future (projected) sales of the market as a whole
XOMA Royalty is a biotech company that monetizes its patent portfolio and royalties from sales of drugs developed by its partners. Its revenue depends on the commercial success of these drugs. This graph, reflecting the state of the economy, indirectly affects overall healthcare spending, which may impact sales of the drugs from which XOMA receives royalties.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772499962357 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality XOMA Royalty
XOMA Royalty specializes in acquiring royalties from pharmaceuticals. Its business model, like EMX's, offers high profitability potential. This chart shows what portion of its partner licensing fees the company converts into net profit, while minimizing operating costs associated with drug development.
Market segment marginality - Invest resource
XOMA Royalty operates a business model based on receiving royalties from pharmaceuticals developed by other companies. It holds a portfolio of potential revenue streams. This chart demonstrates the high operational efficiency typical of royalty companies, which have virtually no research expenses and focus primarily on managing their asset portfolio.
Market marginality as a whole
XOMA Royalty holds a portfolio of royalties and milestone payments from pharmaceutical companies. Its business model is to generate passive income from the success of drugs developed by others. This total market return chart highlights XOMA's unique, low-risk biotech model, which allows it to profit from innovation without the enormous costs of clinical research.
Employees in the company, segment and market as a whole
Number of employees in the company XOMA Royalty
XOMA Royalty holds a portfolio of royalties and license fees from various pharmaceutical and biotech companies. The compact team size, illustrated by this chart, is the essence of its business model. A small staff manages passive cash flows, eliminating the costs and risks of drug development.
Share of the company's employees XOMA Royalty within the market segment - Invest resource
This chart illustrates XOMA Royalty's unique business model. Instead of developing its own drugs, its share of the sector is focused on acquiring royalties from potential future sales of drugs developed by other biotech companies. It's a small team of experts who analyze and acquire stakes in the future success of the pharmaceutical industry.
Number of employees in the market segment - Invest resource
XOMA Royalty owns a portfolio of royalties on various pharmaceuticals. Like EMX in metals, XOMA doesn't develop drugs itself, but rather derives revenue from the success of other companies. This business model requires a small team of biotech and financial experts. This chart demonstrates that there is room for intellectual property-based financial models in the pharmaceutical industry.
Number of employees in the market as a whole
XOMA Corporation owns a portfolio of pharmaceutical royalties. Its revenue depends on the sales success of these drugs, not on the economic cycles shown in this chart. The company represents a diversified bet on biotech innovation, generating passive income from other companies' scientific breakthroughs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company XOMA Royalty (XOMA)
XOMA owns a portfolio of royalties representing potential payouts from successful pharmaceuticals. This graph is the quintessential example of a business built on intellectual property. A minimal staff of financiers and analysts manages rights to future billions of dollars in revenue, resulting in astronomical market capitalization per employee, reflecting the portfolio's value.
%20of%20the%20company%20XOMA%20Royalty%20(XOMA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-XOMA-Royalty-XOMA&v=1772499962387 "Chart of market capitalization per employee (in thousands of dollars) of the company XOMA Royalty (XOMA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Invest resource
XOMA Royalty owns a portfolio of biotech royalties. Its lean business model allows for high efficiency. This chart clearly illustrates how the company generates significant market value by managing the rights to future drug revenues with a very small team.
%20by%20market%20segment%20-%20Invest%20resource&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Invest-resource&v=1772499962390 "Market capitalization per employee (in thousands of dollars) by market segment - Invest resource")
Market capitalization per employee (in thousands of dollars) for the overall market
XOMA Royalty owns a portfolio of potential royalties from pharmaceutical companies. Like EMX, its business model is rights management, not operations. This chart shows a very high cost per employee, as a small staff of lawyers and analysts manages a portfolio with potential revenue in the hundreds of millions.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772499962392 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company XOMA Royalty (XOMA)
XOMA Royalty isn't a biotech company, but a "biotech royalty" company. They don't conduct R&D, but rather purchase rights to future royalties from drugs developed by others. This chart demonstrates the effectiveness of the "light" model. XOMA has a very small staff of financiers and analysts. Their job is to find and acquire assets that will generate passive income.
%20Chart%20XOMA%20Royalty%20(XOMA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-XOMA-Royalty-XOMA&v=1772499962398 "Company Profit Per Employee (in thousands of dollars) Chart XOMA Royalty (XOMA)")
Profit per employee (in thousands of dollars) in the market segment - Invest resource
XOMA Royalty also operates under the royalty model, but in the biotech sector. The company owns a portfolio of rights to future revenues from the sale of drugs developed by other companies. XOMA has a minimal staff. This chart shows how a small team of experts manages a portfolio that generates revenue from other companies' R&D. It serves as a benchmark for assessing the effectiveness of this business model in the pharmaceutical sector, where a single successful patent can generate enormous revenue.
%20in%20the%20market%20segment%20-%20Invest%20resource&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Invest-resource&v=1772499962402 "Chart of profit per employee (in thousands of dollars) in the market segment - Invest resource")
Profit per employee (in thousands of dollars) for the market as a whole
XOMA Royalty (XOMA) is a company that owns a portfolio of royalties and potential payouts from biotech drugs developed by other companies. They have very few employees; their job is to manage this portfolio. This graph, like EMX's, would show very high profit per employee. This is the essence of their model: to earn passive income from the successes of the pharmaceutical industry without incurring R&D costs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772499962404 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee XOMA Royalty (XOMA)
XOMA owns a portfolio of royalties on potential pharmaceuticals. This chart reflects a business model based on passive income. A very small team manages the portfolio, receiving payments from pharmaceutical companies based on the success of their clinical developments. This is an example of high intellectual productivity.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-XOMA-Royalty-XOMA&v=1772499962409 "Sales chart per company employee XOMA Royalty (XOMA)")
Sales per employee in the market segment - Invest resource
XOMA Royalty is a company that receives royalties from various pharmaceuticals developed by other companies. This chart shows the average revenue per employee in the segment. With a small staff, their productivity per employee must be high. The chart allows you to compare the efficiency of their royalty collection model with other companies in the sector.
Sales per employee for the market as a whole
XOMA Royalty is a biotech company with a unique model. They don't develop drugs themselves, but rather acquire the rights to future royalties from drugs developed by others. They're the "Blackstone" of biotech. This metric reflects how their small team of experts negotiates deals that generate passive income from successful drugs.
Short shares by company, segment and market as a whole
Shares shorted by company XOMA Royalty (XOMA)
XOMA Royalty is a company that doesn't develop drugs but rather purchases the rights to future royalties from their sales. The bearish sentiment seen in this chart may reflect concerns about the quality of its portfolio. These bears are betting that the drugs for which XOMA has purchased royalties will not be approved by regulators or will not achieve expected sales.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-XOMA-Royalty-XOMA&v=1772499962418 "Short Shares Chart for the Company XOMA Royalty (XOMA)")
Shares shorted by market segment - Invest resource
XOMA Royalty is a company that doesn't develop drugs, but rather owns a portfolio of royalties and milestones from dozens of drugs developed by other companies. This chart reflects the overall sentiment in the sector. It reflects investor doubts about the sustainability of the "biotech investment" business model, as they anticipate clinical trial failures among XOMA's partners.
Shares shorted by the overall market
XOMA Royalty holds the rights to future royalties from pharmaceutical companies. This "smart money" model avoids R&D risks. However, when this indicator of overall pessimism rises, investors panic. Without understanding the nuances, they simply sell off the entire biotech sector, fearing that the slowdown in innovation will even hurt future royalties.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator XOMA Royalty (XOMA)
XOMA Royalty (XOMA) is a biopharmaceutical royalty company. They don't develop drugs themselves, but rather hold the rights to receive royalties (a percentage of sales) from drugs developed by others. This chart measures momentum. It shows "overbought" (above 70) on news about the success of their portfolio drugs, or "oversold" (below 30) during periods of no news.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-XOMA-Royalty-XOMA&v=1772499962426 "RSI 14 indicator chart for the company's stock XOMA Royalty (XOMA)")
RSI 14 Market Segment - Invest resource
XOMA Royalty (XOMA) is a company that doesn't develop drugs, but rather owns a portfolio of royalties and milestones from other pharmaceutical companies' developments. It's a diversified biotech bet. This chart tracks sentiment in the Resource Investments/Pharma sector. It helps understand whether XOMA is moving in sync with the overall biotech sector or is being valued separately.
RSI 14 for the overall market
XOMA owns a portfolio of pharmaceutical royalties. This chart shows that its business is "defensive." Demand for drugs isn't affected by euphoria or panic. During periods of market panic, investors seek a "safe haven" in the stable, non-cyclical cash flows generated by XOMA's royalties.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast XOMA (XOMA Royalty)
XOMA Royalty (XOMA) is a biotech royalty company. It doesn't develop drugs itself, but rather owns a portfolio of assets (royalties and milestones) that generate income from the success of other pharmaceutical companies. This chart shows the average Wall Street forecast. It reflects analysts' assessments of the likelihood of success for the drugs to which XOMA holds the rights.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-XOMA-XOMA-Royalty&v=1772499962437 "A chart showing analyst consensus forecasts for the expected stock price. XOMA (XOMA Royalty)")
The difference between the consensus estimate and the actual stock price XOMA (XOMA Royalty)
XOMA (XOMA) is a unique royalty aggregator in biotech. They don't conduct R&D, but rather acquire the rights to future royalties from dozens of drugs developed by others. This chart shows their portfolio valuation. It measures the gap between the price and the consensus target, reflecting the potential analysts see in their diversified drug bets.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-XOMA-XOMA-Royalty&v=1772499962440 "A chart showing the difference between the consensus forecast and the actual stock price. XOMA (XOMA Royalty)")
Analyst consensus forecast for stock prices by market segment - Invest resource
XOMA is a biotech "investment fund." The company doesn't research drugs itself, but rather holds a portfolio of royalties (shares) from sales of drugs developed by giants like Merck and Novartis. This chart shows general expectations for the investment resource sector (and pharma). It reflects whether experts believe in the commercial success of the R&D pipeline across the entire biotech industry.
Analysts' consensus forecast for the overall market share price
XOMA Royalty is a unique company. They don't develop drugs, but rather hold a portfolio of royalties and milestones (success fees) from numerous drugs developed by other companies. This chart shows their overall risk appetite. For XOMA, whose business is a diversified portfolio of biotech bets, overall optimism is important, but their revenue depends on the success of other companies' labs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index XOMA Royalty
XOMA Royalty (XOMA) is a unique portfolio. They don't develop drugs, but rather acquire future royalty streams (milestones and royalties) from dozens of biotech companies in the early stages of R&D. This chart is a biotech lottery ticket. Its valuation isn't profit, but the discounted value of their massive, diversified (but high-risk) portfolio of hopes for future scientific breakthroughs.
AKIMA Market Segment Index - Invest resource
XOMA Royalty (XOMA) is a pharma royalty aggregator; the company (unlike Royalty Pharma) doesn't purchase large royalties, but rather acquires portfolios of early-stage (pre-clinical, Phase I) assets and patents in exchange for future payments. This aggregate metric evaluates R&D. The chart shows the average value for the segment. This benchmark: how does XOMA's unique venture (R&D) model differentiate it from the average pharma company?
The AKIM Index for the overall market
XOMA is a biotech company specializing in acquiring royalties from sales of drugs developed by others. This chart, reflecting the market average, is a backdrop. It helps assess how this unique financial instrument in the pharmaceutical industry, which diversifies development risks, compares to overall economic trends.
